55 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
activities, provided that such engagement does not interfere with Executive’s duties and responsibilities hereunder.
(c)During the Employment Period … by Executive may result in the withdrawal of the offer of engagement or the termination of Executive’s employment with the Company. Immediately upon
8-K
EX-10.4
u1xv1te
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
6k7vzrs4lq
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
5coyu71jqy1
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
3cbai vlybm3m4sx
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
uj3k0 ulr9x893lfqe4
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
czdmi
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
vgudnk
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.1
zr3u eyfc6ojqv
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.01
v4p265 me
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-99.1
vemwwre
13 Sep 21
Other Events
7:08am